Calyx (clinical research company)
| Company type | Private |
|---|---|
| Industry | Clinical research organizations Pharmaceutical |
| Founded | 2021 |
| Headquarters | Nottingham, United Kingdom[1] |
Number of locations | 12+ facilities in 10+ countries |
Key people | CEO: David Herron |
| Services | Medical imaging, clinical trial management systems |
| Revenue |  $82 million (2022)[2][3] |
Number of employees | 1000-2000[4] |
| Parent | CapVest Partners/GLO Healthcare |
| Website | calyx |
Calyx, formerly Parexel Informatics,[5] is a corporate spin-off from Parexel International.[2][6] Calyx is a British–American provider of biopharmaceutical services.[7] The company was formed in January 2021 following the strategic separation of the Parexel Informatics business from Parexel International, and provides medical imaging, e-clinical and regulatory services.[8]
References
[edit]- ^ https://www.calyx.ai/locations/
- ^ a b "Merck and Veeva Ink 10-Year Partnership Agreement". BioPharm International.
- ^ "Calyx Partnership with Top 5 CRO Extended through 2024". finance.yahoo.com.
- ^ "Company".
- ^ https://www.clinicalresearchnewsonline.com/news/2022/06/10/calyx-named-medical-imaging-provider-by-clinscience
- ^ "Calyx Spins Out of Parexel". Applied Clinical Trials Online.
- ^ "Announcing Calyx: Advancing Clinical Research Through Technology-Enabled Services".
- ^ "Announcing Calyx: Advancing Clinical Research Through Technology-Enabled Services". Retrieved 29 March 2023.
 | This corporation or company article is a stub. You can help Wikipedia by expanding it. |